10:00 AM EST - Tetra Bio-Pharma Inc. : Conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its non-controlled cannabinoid drug product PPP003 slated for the treatment of painful dry eye. The purpose of the meeting was to obtain confirmation of the Phase II clinical study design and the quality and toxicology requirements for initiating this trial in patients in the U.S. Tetra Bio-Pharma Inc.
shares V.TBP are trading down $0.01 at $0.51.
